glp-1 ra drug names What to Make of the Coverage and Cost Landscape How to Find a Health
Description
Real-world Evidence: There is mounting evidence that GLP-1 agonists administered for diabetes or obesity correspond to reduced addiction risk
This aspect of appetite regulation is crucial for those looking to achieve sustainable weight loss and body contouring goals
The FDA has not said when it would announce a decision about weight loss approval for Mounjaro, but consensus expectations place it sometime in Q4 23 = Q1 24
doi: 10.1111/dom.13053
Exenatide The FDA OKd exenatide in 2005, making it the first approved GLP-1 for Type 2 diabetes
Aviles-Olmos I, Dickson J, Kefalopoupou Z, Djamshidian A, Kahan J, Ell P, et al
